Gilead Acquires CymaBay in $4.3 Billion Deal
Key Highlights Gilead Sciences announces acquisition of CymaBay Therapeutics for $4.3 billion, bolstering its liver disease treatment offerings. Seladelpar, CymaBay’s lead product…
Browsing Tag
Sujal Shah
1 post